Drugs & Targets EC approves Kymriah in relapsed or refractory follicular lymphoma May 06, 2022Vol.48 No.18
Drugs & Targets EC approves Cabometyx as a second-line treatment for radioactive iodine-refractory differentiated thyroid cancer May 06, 2022Vol.48 No.18
Drugs & Targets Myriad Genetics expands partnership with Intermountain Precision Genomics, adding liquid biopsy therapy selection offering May 06, 2022Vol.48 No.18
Drugs & Targets Aadi Bioscience issues unique permanent J-code for Fyarro from CMS May 06, 2022Vol.48 No.18
Regulatory News As part of Cancer Moonshot, FDA seeks to prohibit menthol cigarettes, flavored cigars April 29, 2022Vol.48 No.17By Paul Goldberg
In Brief MD Anderson, Community Health Network announce partnership to create fully integrated cancer program April 29, 2022Vol.48 No.17
In Brief Shelley Johns named inaugural Walther Scholar in Psycho-Oncology at IU School of Medicine April 29, 2022Vol.48 No.17
In Brief UC Davis Comprehensive Cancer Center establishes Center for Advancing Cancer Health Equity April 29, 2022Vol.48 No.17
In Brief ACS, St. Baldrick’s Foundation award $1.2M in research grants for childhood cancer treatments April 29, 2022Vol.48 No.17
